Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,021 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study.
Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. Hu P, et al. Among authors: gong g. J Clin Transl Hepatol. 2018 Mar 28;6(1):25-34. doi: 10.14218/JCTH.2017.00072. Epub 2018 Mar 17. J Clin Transl Hepatol. 2018. PMID: 29577029 Free PMC article.
Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings.
Xu DZ, Wang XY, Shen XL, Gong GZ, Ren H, Guo LM, Sun AM, Xu M, Li LJ, Guo XH, Zhen Z, Wang HF, Gong HY, Xu C, Jiang N, Pan C, Gong ZJ, Zhang JM, Shang J, Xu J, Xie Q, Wu TF, Huang WX, Li YG, Xu J, Yuan ZH, Wang B, Zhao K, Wen YM; YIC Efficacy Trial Study Team. Xu DZ, et al. J Hepatol. 2013 Sep;59(3):450-6. doi: 10.1016/j.jhep.2013.05.003. Epub 2013 May 11. J Hepatol. 2013. PMID: 23669281 Clinical Trial.
Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection.
Rao H, Wei L, Lopez-Talavera JC, Shang J, Chen H, Li J, Xie Q, Gao Z, Wang L, Wei J, Jiang J, Sun Y, Yang R, Li H, Zhang H, Gong Z, Zhang L, Zhao L, Dou X, Niu J, You H, Chen Z, Ning Q, Gong G, Wu S, Ji W, Mao Q, Tang H, Li S, Wei S, Sun J, Jiang J, Lu L, Jia J, Zhuang H. Rao H, et al. Among authors: gong z, gong g. J Gastroenterol Hepatol. 2014 Mar;29(3):545-53. doi: 10.1111/jgh.12398. J Gastroenterol Hepatol. 2014. PMID: 24090188 Free PMC article.
[High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-na(i)ve patients: a multicenter randomized study].
Chen X, Shang J, Yang R, Xie Q, Gao Z, Xu X, Dou X, Gong G, Chen G, Li J, Chen H, Zhang D, Feng Y, Niu J, Hou J, You H, Wu Y, Zhao P, Rao H, Wei L. Chen X, et al. Among authors: gong g. Zhonghua Gan Zang Bing Za Zhi. 2015 Jun;23(6):412-7. doi: 10.3760/cma.j.issn.1007-3418.2015.06.004. Zhonghua Gan Zang Bing Za Zhi. 2015. PMID: 26236925 Clinical Trial. Chinese.
[The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients].
Rao H, Yang R, Shang J, Xu X, Chen X, Dou X, Feng Y, Gao Z, Xie Q, Li J, You H, Chen G, Niu J, Gong G, Hou J, Chen H, Zhang D, Wei L. Rao H, et al. Among authors: gong g. Zhonghua Nei Ke Za Zhi. 2015 Aug;54(8):699-704. Zhonghua Nei Ke Za Zhi. 2015. PMID: 26674626 Clinical Trial. Chinese.
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Wei L, Zhang M, Xu M, Chuang WL, Lu W, Xie W, Jia Z, Gong G, Li Y, Bae SH, Yang YF, Xie Q, Lin S, Chen X, Niu J, Jia J, Garimella T, Torbeyns A, McPhee F, Treitel M, Yin PD, Mo L. Wei L, et al. Among authors: gong g. J Gastroenterol Hepatol. 2016 Nov;31(11):1860-1867. doi: 10.1111/jgh.13379. J Gastroenterol Hepatol. 2016. PMID: 27003037 Clinical Trial.
Analysis of immunological mechanisms exerted by HBsAg-HBIG therapeutic vaccine combined with Adefovir in chronic hepatitis B patients.
Zhou C, Li C, Gong GZ, Wang S, Zhang JM, Xu DZ, Guo LM, Ren H, Xu M, Xie Q, Pan C, Xu J, Hu Z, Geng S, Zhou X, Wang X, Zhou X, Mi H, Zhao G, Yu W, Wen YM, Huang L, Wang XY, Wang B. Zhou C, et al. Among authors: gong gz. Hum Vaccin Immunother. 2017 Sep 2;13(9):1989-1996. doi: 10.1080/21645515.2017.1335840. Epub 2017 Jun 30. Hum Vaccin Immunother. 2017. PMID: 28665747 Free PMC article.
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
Wei L, Xie Q, Hou JL, Jia J, Li W, Xu M, Li J, Wu S, Cheng J, Jiang J, Wang G, Yang Y, Mou Z, Gao ZL, Gong G, Niu JQ, Hu P, Tang H, Lin F, Dou X, Li L, Zhang LL, Nan Y, Massetto B, Yang JC, Knox SJ, Kersey K, German P, Mo H, Jiang D, Brainard DM, Jiang J, Ning Q, Duan Z. Wei L, et al. Among authors: gong g. J Gastroenterol Hepatol. 2018 Jun;33(6):1168-1176. doi: 10.1111/jgh.14102. Epub 2018 Mar 25. J Gastroenterol Hepatol. 2018. PMID: 29380415 Clinical Trial.
Ledipasvir/sofosbuvir for treatment-naive and treatment-experienced Chinese patients with genotype 1 HCV: an open-label, phase 3b study.
Wei L, Xie Q, Hou JL, Tang H, Ning Q, Cheng J, Nan Y, Zhang L, Li J, Jiang J, McNabb B, Zhang F, Camus G, Mo H, Osinusi A, Brainard DM, Gong G, Mou Z, Wu S, Wang G, Hu P, Gao Y, Jia J, Duan Z. Wei L, et al. Among authors: gong g. Hepatol Int. 2018 Mar;12(2):126-132. doi: 10.1007/s12072-018-9856-z. Epub 2018 Apr 10. Hepatol Int. 2018. PMID: 29637511 Free PMC article. Clinical Trial.
2,021 results